Advice

In the absence of a submission from the holder of the marketing authorisation:

glibenclamide (Amglidia®) is not recommended for use within NHSScotland.

Indication under review: Treatment of neonatal diabetes mellitus, for use in newborns, infants and children.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice366KB (PDF)

Download

Medicine details

Medicine name:
glibenclamide (Amglidia)
SMC ID:
SMC2237
Indication:

Treatment of neonatal diabetes mellitus, for use in newborns, infants and children.

Pharmaceutical company
Amring Pharma
BNF chapter
Endocrine system
Submission type
Non submission
Status
Not recommended
Date advice published:
07 October 2019